Detalles de la búsqueda
1.
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
Hematol Oncol
; 42(1): e3222, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37740931
2.
Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis.
Br J Clin Pharmacol
; 90(3): 748-758, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37855131
3.
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Blood
; 138(10): 836-846, 2021 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34115103
4.
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Hematol Oncol
; 40(2): 269-279, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35043428
5.
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Am J Hematol
; 96(4): 418-427, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33368455
6.
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Jpn J Clin Oncol
; 51(6): 857-864, 2021 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33712849
7.
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
Lancet Oncol
; 21(4): 551-560, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32171069
8.
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Blood
; 130(22): 2392-2400, 2017 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28847998
9.
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Hematol Oncol
; 37(4): 464-473, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31251400
10.
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(1): 65-75, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29246803
11.
Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials.
Hematol Oncol
; 2018 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29672885
12.
Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.
Hematol Oncol
; 36(1): 37-43, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28707346
13.
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Eur J Clin Pharmacol
; 74(4): 413-421, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29302721
14.
Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
Xenobiotica
; 48(9): 904-910, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29027832
15.
Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.
Drug Metab Dispos
; 45(3): 294-305, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27993930
16.
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Hematol Oncol
; 35(4): 679-684, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27982454
17.
Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.
Anticancer Drugs
; 28(8): 911-914, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28562380
18.
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Br J Clin Pharmacol
; 83(4): 846-854, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27859472
19.
No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.
Antimicrob Agents Chemother
; 60(1): 400-8, 2016 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26525798
20.
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.
Antimicrob Agents Chemother
; 58(1): 136-43, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24145522